PGY2 Oncology Residency Pharmacy

Purpose

PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.

Program Structure

The PGY2 Oncology Pharmacy Residency at MUSC is a second-year post-graduate training program designed to develop essential knowledge and skills necessary to become an oncology pharmacy clinical specialist and obtain oncology pharmacy board certification. The residency program provides the flexibility to adapt to the resident’s specific learning needs and goals. The training is provided through month-long clinical rotations and longitudinal experiences that extend throughout the year.

Required Learning Experiences:

1. PGY2 Oncology Orientation (July, 1 month)
2. PGY2 Oncology Inpatient Malignant Hematology (1 month)
3. PGY2 Oncology Outpatient Malignant Hematology (1 month)
4. PGY2 Oncology Outpatient BMT & Cellular Therapy Clinic (1 month)
5. PGY2 Oncology Outpatient Oncology I, II, III, IV, & V (5 months); includes the following clinic options based on resident preference and preceptor availability:
   1. Breast cancer
   2. Gastrointestinal cancer
   3. Genitourinary with head and neck cancer
   4. Gynecologic oncology
   5. Neurologic oncology
   6. Sarcoma and melanoma
   7. Thoracic oncology
6.  PGY2 Oncology Project Month (December, 1 month)
7. PGY2 Oncology Outpatient Multispecialty Solid Tumor (1 month)

Elective Learning Experiences:

• PGY2 Oncology Elective Outpatient Breast Clinic (1 month)
• PGY2 Oncology Elective Pediatric Hematology (1 month)
• PGY2 Oncology Elective Infectious Diseases (1 month)
• PGY2 Inpatient Malignant Hematology Elective (1 month)
• PGY2 Hematopoietic Stem Cell Transplantation & Cellular Therapy (inpatient/outpatient) (1 month)
• PGY2 Elective Oncology Outpatient Malignant Hematology (1 month)
• PGY2 Elective Inpatient Solid Tumor Rotation (1 month)

Longitudinal

• PGY2 Oncology Longitudinal Oncology Topic Discussions Quarter 1-4 (assigned each quarter)
• PGY2 Longitudinal Oncology Practice Management (6 months, July – December)
• PGY2 Oncology Longitudinal Inpatient Staffing (1 year)
• PGY2 Oncology Longitudinal Outpatient Staffing (6 months)
• PGY2 Oncology Longitudinal Investigational Drug Services (1 year)
• PGY2 Longitudinal Capstone Solid Tumor Rotation (6 months in a single clinic); includes the following clinic options based on resident preference and preceptor availability: 
  • Breast cancer
  • Thoracic oncology
• PGY2 Oncology Longitudinal MUE (5 months)
• PGY2 Oncology Longitudinal Research Project (1 year)
• PGY2 Oncology Seminar (2 months)
• PGY2 Oncology Didactic Lecture (2 months)

Additional program-specific completion requirements:

• Up to 26, 10-hour weekend shifts covering inpatient oncology unit (average of every 4th weekend over 52 weeks)
• 2 staffing days per month in outpatient infusion center from August to December (total of 11, 8-hour shifts)
• 1 month precepting or longitudinal mentoring a PGY1 resident or P4 pharmacy student
• Attendance and poster presentation at HOPA (yearlong project presentation)
• If also attending Midyear, Vizient poster presentation encouraged for MUE

Core Preceptors:

Lauren Blackwell, PharmD, BCOP
Clinical Oncology Specialist, Thoracic Oncology

Jennifer Carter, PharmD, BCPS
Director, Specialty Pharmacy

Alyssa Cendagorta, PharmD, BCOP
Clinical Oncology Specialist, BMT/Cellular Therapy and Malignant Hematology (Inpatient)

James Davis, PharmD, BCOP
Clinical Oncology Specialist, Malignant Hematology (Outpatient)

Anastasia Graham, PharmD, BCOP, MBA
Clinical Oncology Specialist, Neurologic Oncology

Katelynn Granger, PharmD
Clinical Oncology Specialist, Malignant Hematology (Outpatient)

Julie Heh, PharmD, BCPS, BCPPS
Clinical Pediatric Specialist, Pediatric Oncology

Christina Hoppe, PharmD, BCOP, MBA
Clinical Oncology Specialist, Outpatient Solid Tumor, Palliative Care

Kasey Jackson, PharmD, BCOP
Clinical Oncology Specialist, Breast Oncology

Jennifer MacDonald, PharmD, BCOP
Clinical Oncology Specialist, Gynecologic Oncology

Andy Maldonado, PharmD, BCOP
Clinical Oncology Specialist, Faculty MUSC College of Pharmacy, Sarcoma, Melanoma and Skin Cancers

Jessica Marini, PharmD, BCOP
Clinical Oncology Specialist, BMT/Cellular Therapy (Outpatient)

Mary McGann, PharmD, BCOP
Clinical Oncology Specialist, BMT/Cellular Therapy (Outpatient)

Jagoda Misniakiewicz, PharmD
Clinical Oncology Specialist, Gastrointestinal Oncology

Kiera Roubal, PharmD, BCOP
Clinical Oncology Specialist, Breast and Gynecologic Oncology

Deidra Smith, PharmD, BCOP
Clinical Oncology Specialist, Malignant Hematology (Outpatient)

Sherry Vogt, PharmD, BCOP
Clinical Oncology Specialist, Genitourinary and Head/Neck Oncology

Matt Warrick, PharmD, BCOP
Clinical Oncology Specialist, BMT/Cellular Therapy and Malignant Hematology (Inpatient)

Current Residents

PGY2 Oncology Pharmacy Residents